The abstract is read at the publisher; the summary is JClub's.
Transcatheter tricuspid-valve repair plus medical therapy improves a 1-year hierarchical composite outcome in 360 patients with symptomatic severe tricuspid regurgitation, with a win ratio of 2.42.
- Why it matters: The benefit of transcatheter tricuspid-valve repair for clinical outcomes, including death and heart-failure hospitalization, in high-risk patients with severe tricuspid regurgitation is uncertain.
- What they did: In a randomized trial, 237 patients received tricuspid-valve repair plus medical therapy and 123 received medical therapy alone, with the primary outcome assessed by win ratio at 1 year.
- The result: Through 3 years, freedom from death or heart-failure hospitalization was 52.4% versus 21.0% (hazard ratio 0.40; P<0.001), with major adverse events within 30 days in 5.9%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.